



Translation

March 18, 2019

Company name: RIBOMIC Inc.
Representative: Yoshikazu Nakamura, President and CEO
Stock code: 4591
Listing: Tokyo Stock Exchange, Mothers Market
Contact: Emiko Nakamura, Board Director,
Corporate Planning Department

Initiation of Cohort 3 in Clinical Trial of RBM-007 for Treatment of Exudative Age-related Macular Degeneration

We are pleased to announce that first patient of Cohort 3 has been enrolled and treated with RBM-007 in the phase I/IIa trial for the treatment of exudative age-related macular degeneration (AMD) in the United States. Upon completion of the RBM-007 injection by all 3 subjects in Cohort 2, the external safety review team assessed them and recommended to proceed to the final Cohort 3 (the cohort with next dose) since no safety concerns were raised in any of the Cohort 2 subjects, as is the case in the Cohort 1.

This PI/IIa trial is an open label, non-controlled, dose-escalating study assessing mainly the safety and tolerability of a single intravitreal injection of RBM-007 in approximately nine subjects.

See ClinicalTrials.gov for more information.

<https://clinicaltrials.gov/ct2/show/NCT03633084>